Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Life Time is set to break out to record highs on its preliminary Q4 results, 2025 outlook. Planet Fitness scored a breakout ...

Meme stocks like AMC Entertainment and GameStop get their price spikes from exceptional buying interest. Adding to that risk, ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...